Monica Forbes
Corporate Officer/Principal presso APOGEE THERAPEUTICS, INC.
Patrimonio netto: 33 626 $ in data 31/05/2024
Provenienza dei contatti di primo grado di Monica Forbes
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Subsidiary | Pharmaceuticals: Major | 24 | |
| Extinct | Pharmaceuticals: Major | 23 | |
| Public Company | Biotechnology | 19 | |
Nalpropion Pharmaceuticals, Inc.
 Nalpropion Pharmaceuticals, Inc. Managed Health CareHealth Services Nalpropion Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the treatment of weight loss. Its products include CONTRAVE, analtrexone HCl & bupropion HCl extended release and Mysimba, a naltrexone HCl/ bupropion HCl prolonged release. The company is headquartered in Morristown, NJ.
1
| Subsidiary | Managed Health Care | 1 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Monica Forbes tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| Stanford University | College/University | Undergraduate Degree Graduate Degree Doctorate Degree Doctorate Degree | |
| The Trustees of Columbia University in The City of New York | College/University | Graduate Degree Graduate Degree Graduate Degree Graduate Degree | |
| SPYRE THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| University of California, Irvine | College/University | Corporate Officer/Principal Masters Business Admin Doctorate Degree | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Sales & Marketing Sales & Marketing Director of Finance/CFO | |
| TREVENA, INC. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal Corporate Officer/Principal | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Sales & Marketing General Counsel Corporate Officer/Principal | |
| University of California, Santa Barbara | College/University | Undergraduate Degree Graduate Degree Undergraduate Degree | |
| BRIDGEBIO PHARMA, INC. | Biotechnology | Corporate Officer/Principal Human Resources Officer Corporate Officer/Principal | |
| UCLA School of Law | College/University | Graduate Degree Graduate Degree | |
| ATARA BIOTHERAPEUTICS, INC. | Pharmaceuticals: Major | General Counsel Director/Board Member | |
| SANGAMO THERAPEUTICS, INC. | Biotechnology | General Counsel Investor Relations Contact | |
| SPECTRUM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Comptroller/Controller/Auditor | |
| PHASEBIO PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal General Counsel | |
Ascenta Therapeutics, Inc.
 Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| INVIVYD, INC. | Biotechnology | Chief Tech/Sci/R&D Officer Director of Finance/CFO | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Undergraduate Degree Undergraduate Degree | |
| EYEPOINT PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
| EQUILLIUM, INC. | Biotechnology | Director/Board Member Director of Finance/CFO | |
Domain Associates LLC
 Domain Associates LLC Investment ManagersFinance Domain Associates LLC (Domain Associates) is a venture capital firm founded in 1985. The firm is headquartered in Princeton, New Jersey. | Investment Managers | Private Equity Investor Consultant / Advisor | |
| University of Redlands | College/University | Masters Business Admin Masters Business Admin | |
| METACRINE, INC. | Biotechnology | Chief Executive Officer Chief Executive Officer | |
| Southern Illinois University | College/University | Masters Business Admin Undergraduate Degree | |
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Origin Biosciences, Inc.
 Origin Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., Origin Biosciences, Inc. is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector. The company is based in Palo Alto, CA. The company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify and invest in leading and emerging companies focused on the emerging psychedelics sector. Michael Henderson has been the CEO of the company since 2018. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
QED Therapeutics, Inc.
 QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Pharmaceuticals: Major | Chief Executive Officer Chief Tech/Sci/R&D Officer | |
| San Diego State University | College/University | Undergraduate Degree Undergraduate Degree | |
| REGULUS THERAPEUTICS INC. | Pharmaceuticals: Major | Chief Executive Officer President | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
Duke University
 Duke University Other Consumer ServicesConsumer Services Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC. | College/University | Undergraduate Degree Graduate Degree | |
BioVascular, Inc.
 BioVascular, Inc. Pharmaceuticals: MajorHealth Technology BioVascular, Inc. develops drugs and devices for control of intimal hyperplasia associated with vascular procedures. It is a integrated specialty cardiovascular therapeutic company, and to utilize corporate partnerships in markets that have complex marketing barriers and/or combination technologies. The company was founded by John H. Parrish and Paul F. Glidden in 2005 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
PowerVision, Inc.
 PowerVision, Inc. Electronic ComponentsElectronic Technology PowerVision, Inc. develops fluid-controlled intraocular lens. The firm provides FluidVision accommodating intraocular lens technology, which restores the vision of youth to middle aged or elderly individuals affected by presbyopia and cataracts regain to adjust focus for clear vision at all distances. The company was founded by Matthew A. Frinzi, Randy McDonald, and Barry Cheskin in 2002 and is headquartered in Belmont, CA. | Electronic Components | Director/Board Member Chief Executive Officer | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal General Counsel | |
| BLUEBIRD BIO, INC. | Biotechnology | Director/Board Member Chairman | |
Edimer Pharmaceuticals, Inc.
 Edimer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edimer Pharmaceuticals, Inc. provides biopharmaceutical products for improving the health and quality of life of families living with XLHED. It has developed EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), which is a rare orphan disease that causes symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. The company was founded by Pascal Schneider and Olivier Gaide in 2009 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Venrock Associates
 Venrock Associates Investment ManagersFinance Venrock Associates is an Independent Venture Capital firm founded in 1969. The firm is headquartered in Palo Alto. | Investment Managers | Private Equity Investor Private Equity Investor | |
| Rutgers State University of New Jersey | College/University | Undergraduate Degree Undergraduate Degree | |
| Columbia Business School | College/University | Masters Business Admin Masters Business Admin | |
| VOYAGER THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director of Finance/CFO | |
| VIRIDIAN THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Ren Pharmaceuticals, Inc.
 Ren Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ren Pharmaceuticals was formed in the fall of 2006 with the aim of bringing together talented and experienced people who are passionate about building a cardio-renal/renal- focused drug development company. Ren Pharmaceuticals closed a Series A financing in November 2006 with Sanderling Ventures, Venrock Associates and Amgen Ventures as investors. The company's R&D is currently located in South San Francisco, California. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member | |
Viridian LLC
 Viridian LLC BiotechnologyHealth Technology Viridian LLC operates as a biopharmaceutical incubator. It focuses in the discovery and development of new molecular entities. The company was founded by Peter Harwin and Tomas Kiselak in 2016 and is headquartered in Philadelphia, PA. | Biotechnology | Founder Founder | |
| Emory University | College/University | Undergraduate Degree Masters Business Admin | |
| PROMETHEUS BIOSCIENCES, INC. | Biotechnology | Investor Relations Contact Chief Executive Officer |
Statistiche
Distribuzione geografica
| Stati Uniti | 48 |
| Australia | 2 |
| Svizzera | 2 |
| Francia | 2 |
Settori
| Health Technology | 33 |
| Consumer Services | 15 |
| Finance | 3 |
| Commercial Services | 2 |
| Electronic Technology | 2 |
Posizioni
| Director/Board Member | 206 |
| Corporate Officer/Principal | 114 |
| Independent Dir/Board Member | 79 |
| Chairman | 53 |
| Undergraduate Degree | 53 |
Contatti più connessi
| Insiders | |
|---|---|
| Eckard Weber | 46 |
| Brian H. Dovey | 40 |
| Daniel Lynch | 32 |
| Louis C. Bock | 27 |
| Wendy Dixon | 25 |
| Jane Henderson | 25 |
| Peter Honig | 20 |
| Deborah Jorn | 20 |
| David Endicott | 18 |
| Richard Fitzgerald | 17 |
| Preston Klassen | 15 |
| Joseph Hagan | 15 |
| William Jones | 14 |
| Michael Henderson | 14 |
| Patrick Mahaffy | 13 |
- Borsa valori
- Insiders
- Monica Forbes
- Connessioni Società
